Zoey Becker

After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its eleventh U.S.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

A year after a major layoff round at its Allergan Aesthetics headquarters in California, AbbVie is making more edits to its aesthetics workforce with a new round of 85 layoffs.

A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a buyout offer from Curium Pharma, Bloomberg

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the drug has demonstr

With China's growing dominance in the biopharma sector as a hotspot for drug assets, a collection of global pharma leaders took a trip to its neighbor Japan this week to discuss efforts to boost life sciences leadership prospects with Prime Minister Sanae Takaichi.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap.

More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions attributed to its $3 billion cost-cutting plan announced last July.